Natera, Inc. $NTRA Shares Sold by Kornitzer Capital Management Inc. KS

Natera logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Kornitzer Capital Management cut its Natera stake by 28.3% in the third quarter, selling 7,250 shares and retaining 18,387 shares valued at about $7.6 million.
  • Natera’s quarterly revenue rose 34.1% year over year to about $794 million, exceeding estimates, but its per-share loss of $0.42 was wider than analysts expected.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $391.69; the article also noted leadership uncertainty as CEO Steve Chapman prepares to step down.
  • MarketBeat previews top five stocks to own in December.

Kornitzer Capital Management Inc. KS reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 28.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,387 shares of the medical research company's stock after selling 7,250 shares during the period. Kornitzer Capital Management Inc. KS's holdings in Natera were worth $7,600,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Natera during the 2nd quarter valued at approximately $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the 2nd quarter valued at approximately $1,537,000. Eagle Health Investments LP acquired a new position in Natera in the second quarter valued at approximately $4,302,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Natera in the second quarter valued at approximately $11,695,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Royal Bank Of Canada raised their target price on Natera from $350.00 to $460.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Robert W. Baird set a $348.00 target price on Natera in a research report on Friday, August 7th. Roth Capital started coverage on Natera in a research note on Thursday, October 22nd. They issued a "buy" rating and a $475.00 price target on the stock. Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. Finally, Zacks Research downgraded Natera from a "hold" rating to a "strong sell" rating in a research report on Friday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $391.69.

Check Out Our Latest Analysis on NTRA

Natera Stock Performance

Shares of NTRA stock opened at $310.67 on Friday. The firm's 50 day moving average price is $380.25 and its 200-day moving average price is $269.68. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41. The firm has a market cap of $44.78 billion, a P/E ratio of -272.52 and a beta of 1.55.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 8.73% and a negative net margin of 5.66%. The company had revenue of $793.98 million for the quarter, compared to analysts' expectations of $707.54 million. During the same period in the previous year, the business posted ($0.64) EPS. The business's revenue for the quarter was up 34.1% on a year-over-year basis. As a group, research analysts predict that Natera, Inc. will post -1.14 EPS for the current fiscal year.

Key Stories Impacting Natera

Here are the key news stories impacting Natera this week:

  • Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794 million, beating analyst expectations. Natera also raised its fiscal 2026 sales outlook, supporting the growth outlook for its testing business. Natera Q3 results and outlook
  • Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could broaden access to the cancer-monitoring test and support adoption. Medicare coverage for Signatera in HCC
  • Neutral Sentiment: JPMorgan lowered its price target from $460 to $405 but maintained an Overweight rating, indicating continued confidence while marking down its valuation expectations. JPMorgan price-target update
  • Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition. The announcement weighed on sentiment despite the stronger revenue outlook. CEO transition and market reaction
  • Negative Sentiment: The quarterly per-share loss was wider than analysts expected (about $0.42 versus a $0.28 consensus loss), despite revenue beating estimates. This earnings miss appears to have contributed to the selloff. Natera third-quarter financial results

Insider Transactions at Natera

In other news, insider John Fesko sold 6,517 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the transaction, the insider directly owned 197,257 shares in the company, valued at $63,424,043.21. This trade represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of Natera stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the sale, the chief executive officer directly owned 87,431 shares of the company's stock, valued at $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 53,573 shares of company stock valued at $19,856,400 over the last three months. 5.05% of the stock is currently owned by company insiders.

Natera Company Profile

(Free Report)

Natera, Inc is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring.

In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

The company also provides Prospera, a molecular test used to help assess organ transplant rejection.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Natera Right Now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines